Clinical Trials Sponsored by Cook Ireland, Ltd.

Total 129 results

Cook Group Incorporated
Cook Ireland, Ltd.; Cook Biotech Incorporated

Completed

A Randomized Clinical Trial Comparing Surgisis AFP to Advancement Flap for the Repair of Anal Fistulas (Surgisis® AFP)

Anal Fistula

Germany
Foundation for Liver Research
Cook Ireland, Ltd.

Completed

Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS (ASPRO)

Pancreatic Masses | Lymph Nodes

France, Sweden, Israel, Belgium, Australia, United States, Italy, Japan, Netherlands, Spain
Cook Group Incorporated
William Cook Europe; MED Institute, Incorporated; William Cook Australia; Cook...

Completed

Celect Vena Cava Filter Clinical Trial

Venous Thromboembolism | Pulmonary Embolism

United Kingdom, Australia, Germany, Mexico, Spain
Horizon Pharma Ireland, Ltd., Dublin Ireland

Recruiting

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Sjögren's Syndrome (SS)

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Enrolling by invitation

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Korea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis (SUNRAY)

Rheumatoid Arthritis
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders

Urea Cycle Disorders

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (HALT-HE)

Hepatic Encephalopathy | Cirrhosis

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

Osteoarthritis | Rheumatoid Arthritis | Chronic Low Back Pain | Chronic Regional Pain Syndrome | Chronic Soft Tissue Pain

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers

Peptic Ulcer
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Drug Toxicity

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Terminated

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

Hepatic Encephalopathy

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

Ulcer
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
University College Cork
APC Microbiome Ireland

Recruiting

Microbiome in the Acute Stage of New Onset Paediatric Type 1 Diabetes

Type 1 Diabetes

Ireland
Cancer Trials Ireland
University College Cork

Active, not recruiting

Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer (Lithium)

Colorectal Neoplasms | Esophageal Neoplasms | Stomach Neoplasm

Ireland
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis (JIA)

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis (CAPRA-2)

Rheumatoid Arthritis

United States, Germany, Hungary, Canada, Poland, United Kingdom
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) (HZ-CA-304)

Osteoarthritis | Rheumatoid Arthritis | Chronic Low Back Pain | Chronic Regional Pain Syndrome | Chronic Soft Tissue Pain

United States
University College Cork
Science Foundation Ireland

Unknown

Learning to Evaluate Blood Pressure at Home (LEANBH) (LEANBH)

Hypertension in Pregnancy

Ireland
Horizon Therapeutics Ireland DAC

Not yet recruiting

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (N-MOmentum LT)

Neuromyelitis Optica Spectrum Disorder
Horizon Therapeutics Ireland DAC

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder

United Kingdom, Brazil, Serbia, United States, Canada, France, Poland, Spain, Sweden, Argentina, Netherlands
Horizon Therapeutics Ireland DAC

Recruiting

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Idiopathic Inflammatory Myositis

Mexico, United States, Spain, Australia, Italy, United Kingdom, Czechia, Brazil, Germany
Horizon Therapeutics Ireland DAC

Recruiting

Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus (RECAST DLE)

Discoid Lupus Erythematosus

United States, Germany, Canada, France, Greece, Denmark, Brazil, Bulgaria, Czechia, Argentina, Poland
Horizon Therapeutics Ireland DAC

Recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Netherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
Horizon Therapeutics Ireland DAC

Completed

Study to Evaluate HZN-457 in Healthy Volunteers

Healthy

New Zealand
Horizon Therapeutics Ireland DAC

Completed

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (MIRROR RCT)

Gout

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Uncontrolled Gout | Kidney Transplant

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout (MIRROR OL)

Gout

United States
Horizon Therapeutics Ireland DAC

Not yet recruiting

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Sjogren's Syndrome
Horizon Therapeutics Ireland DAC

Recruiting

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Gout

United States
Horizon Therapeutics Ireland DAC

Recruiting

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome

United States
Horizon Therapeutics Ireland DAC

Recruiting

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Pregnancy Related | Neuromyelitis Optica Spectrum Disorder

United States
Horizon Therapeutics Ireland DAC

Completed

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Uncontrolled Gout

United States
University College Cork
Health Research Board, Ireland

Completed

The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients

Supplementation | Crohn's Disease | Bone Health

Ireland
BHB Therapeutics, Ireland LTD

Completed

Tolerance and Safety of a Ketone-Promoting Food Ingredient

Tolerance

United States
Indiana University
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Use of ACTIMMUNE in Patients With ADO2

Autosomal Dominant Osteopetrosis Type 2

United States
University College Cork
Royal College of Surgeons, Ireland

Terminated

Study of ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Coronary Artery Disease (ADVANCE-PCI)

Coronary Artery Disease

Ireland
Horizon Therapeutics, LLC

Terminated

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) (THRIVE)

Urea Cycle Disorder

United States
Horizon Therapeutics, LLC

Completed

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Urea Cycle Disorder

United States, Canada
University of Pittsburgh
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation

Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

Hepatic Encephalopathy | Urea Cycle Disorders

Ukraine
University College Cork
Wellcome Trust; Health Research Board, Ireland; Health Service Executive, Ireland

Recruiting

Assessing SleeP IN Infants With Atopic Dermatitis by Longitudinal Evaluation (SPINDLE)

Sleep Disturbance | Atopic Dermatitis

Ireland
Cork University Hospital
National University of Ireland, Galway, Ireland; John Hunter Children's Hospital

Completed

What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With T1DM? (REQINSOIL)

Diabetes Mellitus, Type 1

Ireland
Horizon Therapeutics, LLC

Completed

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Urea Cycle Disorder

United States, Spain, Italy, Switzerland
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)

Healthy

Ukraine

Clinical Trials Sponsored by Cook Ireland, Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations